Trials / Suspended
SuspendedNCT00986284
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
Phase II Study of EGFR Status Based Gefitinib Neoadjuvant Therapy in NSCLC Patients
- Status
- Suspended
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gefitinib | Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients. |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2016-11-01
- Completion
- 2016-11-01
- First posted
- 2009-09-29
- Last updated
- 2015-12-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00986284. Inclusion in this directory is not an endorsement.